Phytopharm surges on weight-loss drug success
The extract is derived from the African Hoodia cactus, which the San bushmen of the Kalahari desert have been eating for thousands of years to stave off hunger during long hunting trips. The cactus contains a molecule that fools the brain into believing the stomach is full. The licence for the molecule, discovered by South African scientists, was sold in 1997 to Phytopharm, which teamed up with Unilever to conduct safety and efficacy studies and bring the weight-loss product to market.
The yet-to-be-named treatment is expected to be launched in 2008, after first-stage tests showed it is commercially viable to produce the extract. Phytopharm and Unilever are embarking on clinical trials in the second stage of the project to make sure it works on humans and is safe to use. At the same time, Unilever is running a separate agronomy programme to determine whether the cactus, which takes 50 years to reach maturity, can be grown commercially.
As part of the 2004 co-operation agreement between the two companies, Unilever committed to an initial payment of £6.5m for the first stage and has now committed a further £3.5m out of a total of up to £21m in payments to Phytopharm. In addition Phytopharm will receive an undisclosed royalty on sales of all products containing the extract.
Richard Dixey, the chief executive of Phytopharm, said: "Our partnership with Unilever provides a fully funded programme and we look forward to generating royalty income from our partner's globally recognised brands."
After the clinical trials, expected to take a year, Unilever will work on the branding and marketing of the product. The consumer giant pumps €1bn (£694m) into research and development each year, the bulk of which is spent on developing "look good, feel good" products such as antioxidants in tea and appetite suppressants.
In January, Phytopharm struck a deal to license its skin treatment for dogs to Schering-Plough's animal health unit, with expected annual sales of up to $40m (£23m). The news on both treatments has given a welcome boost to Phytopharm, which suffered a setback in November when its Alzheimer's drug failed to show benefits in tests. Phytopharm shares closed up 4p at 43p.
- 1 Isis propaganda video shows 25 Syrian soldiers executed by teenage militants in Palmyra
- 2 Number of young homeless people in Britain is 'more than three times the official figures'
- 3 The map showing the most dangerous tourist destinations in Europe, according to the Foreign Office
- 4 Right to die: Belgian doctors rule depressed 24-year-old woman has right to end her life
- 5 The biggest first date turnoff has been revealed
Isis propaganda video shows 25 Syrian soldiers executed by teenage militants in Palmyra
Number of young homeless people in Britain is 'more than three times the official figures'
Van driver who comforted Clark Carlisle and called 999 after suicide attempt dies age 24
Greece debt crisis explainer: A history of just how the country landed itself in such a mess
Greece debt crisis referendum: Greeks want to vote No to austerity – but Yes to Europe
Nathan Collier: Montana man inspired by same-sex marriage ruling requests right to wed two wives
More Britons believe that multiculturalism makes the country worse - not better, says poll
Greece crisis: IMF was pushed around by Angela Merkel and Nicholas Sarkozy – and now it is being humiliated
'I wish the BBC would stop calling it Islamic State' – David Cameron unleashes frustration at broadcaster
Forget little green men – aliens will look like humans, says Cambridge University evolution expert
Girl, 7, stares down hate preacher at Ohio festival with pro-LGBT rainbow flag gesture
iJobs Money & Business
£15000 - £17000 per annum: Recruitment Genius: This company offers a range of ...
£15000 - £16000 per annum: Recruitment Genius: Customer Service Advisors are r...
£20000 - £25000 per annum + OTE £45K: SThree: SThree were established in 1986....
£40000 - £60000 per annum: Recruitment Genius: A Compliance Manager is require...